CN113710250A - 用左旋酮康唑治疗疾病的方法 - Google Patents

用左旋酮康唑治疗疾病的方法 Download PDF

Info

Publication number
CN113710250A
CN113710250A CN202080029583.4A CN202080029583A CN113710250A CN 113710250 A CN113710250 A CN 113710250A CN 202080029583 A CN202080029583 A CN 202080029583A CN 113710250 A CN113710250 A CN 113710250A
Authority
CN
China
Prior art keywords
acceptable salt
pharmaceutically acceptable
levoketoconazole
subject
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080029583.4A
Other languages
English (en)
Chinese (zh)
Inventor
F·科恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Strongbridge Dublin Ltd
Original Assignee
Strongbridge Dublin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72338256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113710250(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Strongbridge Dublin Ltd filed Critical Strongbridge Dublin Ltd
Publication of CN113710250A publication Critical patent/CN113710250A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080029583.4A 2019-03-04 2020-03-02 用左旋酮康唑治疗疾病的方法 Pending CN113710250A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813399P 2019-03-04 2019-03-04
US62/813,399 2019-03-04
PCT/US2020/020644 WO2020180784A1 (en) 2019-03-04 2020-03-02 Methods of treating disease with levoketoconazole

Publications (1)

Publication Number Publication Date
CN113710250A true CN113710250A (zh) 2021-11-26

Family

ID=72338256

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080029583.4A Pending CN113710250A (zh) 2019-03-04 2020-03-02 用左旋酮康唑治疗疾病的方法

Country Status (10)

Country Link
US (5) US11020393B2 (https=)
EP (1) EP3934649A4 (https=)
JP (2) JP7574204B2 (https=)
KR (2) KR102950333B1 (https=)
CN (1) CN113710250A (https=)
AU (2) AU2020232246B2 (https=)
BR (1) BR112021017561A2 (https=)
CA (1) CA3132319A1 (https=)
IL (1) IL286099A (https=)
WO (1) WO2020180784A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7574204B2 (ja) * 2019-03-04 2024-10-28 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233843A1 (en) * 2005-01-10 2009-09-17 Cortendo Invest Ab Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007303219A1 (en) * 2006-10-02 2008-04-10 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
TWI690521B (zh) * 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
US11261157B2 (en) * 2016-12-08 2022-03-01 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
US10512667B2 (en) * 2017-06-27 2019-12-24 The Regents Of The University Of Michigan Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production
JP7574204B2 (ja) * 2019-03-04 2024-10-28 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233843A1 (en) * 2005-01-10 2009-09-17 Cortendo Invest Ab Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Also Published As

Publication number Publication date
AU2025204382A1 (en) 2025-07-03
JP7574204B2 (ja) 2024-10-28
AU2020232246B2 (en) 2025-03-20
KR20260049881A (ko) 2026-04-14
US20200397781A1 (en) 2020-12-24
KR20210135278A (ko) 2021-11-12
US20240148724A1 (en) 2024-05-09
US11278547B2 (en) 2022-03-22
JP7801408B2 (ja) 2026-01-16
WO2020180784A1 (en) 2020-09-10
KR102950333B1 (ko) 2026-04-08
IL286099A (en) 2021-10-31
BR112021017561A2 (pt) 2021-11-09
US11020393B2 (en) 2021-06-01
JP2025026838A (ja) 2025-02-26
EP3934649A1 (en) 2022-01-12
US20210267970A1 (en) 2021-09-02
EP3934649A4 (en) 2022-11-23
US11903940B2 (en) 2024-02-20
US20220387425A1 (en) 2022-12-08
US20250387389A1 (en) 2025-12-25
JP2022522873A (ja) 2022-04-20
US12377096B2 (en) 2025-08-05
CA3132319A1 (en) 2020-09-10
AU2020232246A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
EP2200613B1 (en) Phenazine derivatives and uses thereof
US12036224B2 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
US12285470B2 (en) Trim proteins and galectins cooperate and codirect autophagy and are useful in the treatment of autophagy related diseases
US20220288048A1 (en) Pimavanserin for treating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
JP7801408B2 (ja) レボケトコナゾールによる疾患の処置方法
EP2922546A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
TW201318624A (zh) 包含ｐｇｄ２拮抗劑及組織胺拮抗劑之過敏性鼻炎治療用醫藥
HK40062461A (en) Methods of treating disease with levoketoconazole
CA3238551A1 (en) Methods and compositions for treating cancer
US20210220300A1 (en) Methods of treating disease with dichlorphenamide
TW201625253A (zh) 包含ｐｇｄ２拮抗劑之伴隨過敏性疾病之症狀之治療用醫藥
WO2025110992A1 (en) Method of administering belumosudil for patient subpopulations with hepatic impairment
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
CN107072986A (zh) 无类固醇疾病管理

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062461

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20211126

RJ01 Rejection of invention patent application after publication